PT-141 / Bremelanotide
Also known as: Bremelanotide, Vyleesi
An FDA-approved melanocortin receptor agonist used to treat low sexual desire in premenopausal women. Sold under the brand name Vyleesi, it is one of the few peptides with full FDA approval for a sexual health indication.
How it works
Bremelanotide activates melanocortin receptors (specifically MC3R and MC4R) in the brain, which are involved in sexual arousal and desire. Unlike drugs that increase blood flow (like Viagra), PT-141 works through the central nervous system to boost desire itself. It is injected under the skin at least 45 minutes before anticipated sexual activity.
Common uses
- Hypoactive sexual desire disorder (HSDD) in premenopausal women
- Off-label use for male sexual dysfunction
- Low libido treatment
Side effects
- Nausea (40% of users, especially with first injection)
- Facial flushing (20%)
- Injection site reactions (13%)
- Headache (11%)
- Temporary increase in blood pressure (about 6 mmHg systolic)
- Skin darkening (hyperpigmentation) in about 1% of users, especially on face and gums
Key research
- Two Phase 3 RECONNECT trials led to FDA approval in June 2019 for HSDD in premenopausal women
- Clinical trials showed statistically significant improvement in sexual desire and reduction in distress related to low desire
- Studies in men showed improvement in erectile function, though it is not FDA-approved for this use
Safety notes
- Contraindicated in people with uncontrolled high blood pressure or cardiovascular disease
- Limited to no more than 8 doses per month per FDA labeling
- Hyperpigmentation risk increases with frequent dosing and darker skin tones
- Not approved for men or postmenopausal women
Too many clinics, not enough clarity?
We don't sell peptides. Tell us your goals and we'll connect you with a vetted provider who can figure out what actually makes sense for you.
See what's right for youExplore other peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. One of the most well-studied peptides available.
Tirzepatide
A dual GIP/GLP-1 receptor agonist that has shown even greater weight loss results than semaglutide in head-to-head trials.
BPC-157
A synthetic peptide derived from human gastric juice, studied primarily in animal models for its regenerative and anti-inflammatory properties. Not FDA-approved.
CJC-1295 / Ipamorelin
A commonly paired combination of growth hormone-releasing peptides used to stimulate natural GH production for anti-aging, body composition, and recovery.